EUVIMEDEUVIMED entdecken
Crossref

Improved Cardiac Function in Postischemic Rats Using an Optimized Cardiac Reprogramming Cocktail Delivered in a Single Novel Adeno-Associated Virus

Huanyu Zhou, Jin Yang, Chetan Srinath iD, Aliya Zeng, Iris Wu, Elena C Leon, Tawny Neal Qureshi, Christopher A Reid, Emily R Nettesheim iD, Emma Xu, Zoe Duclos iD, Tamer M A Mohamed iD und 14 weitere

Circulation · 03.10.2023 · 148 (14) · 1099-1112

DOI: 10.1161/circulationaha.122.061542 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Circulation, erschienen am 03.10.2023. Verfasst von Huanyu Zhou und 25 weiteren Autor:innen. Beteiligte Einrichtung: Tenaya Therapeutics, Inc, South San Francisco, CA (H.Z., J.Y., C.S., A.Z., I.W., E.C.L., T.N.Q., C.A.R., E.R.N., E.X., Z.D., T.M.A.M., F.F., A.F., J.…. Hauptthemen laut MEDLINE: Myocardial Infarction, MicroRNAs. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Cardiac reprogramming is a technique to directly convert nonmyocytes into myocardial cells using genes or small molecules. This intervention provides functional benefit to the rodent heart when delivered at the time of myocardial infarction or activated transgenically up to 4 weeks after myocardial infarction. Yet, several hurdles have prevented the advancement of cardiac reprogramming for clinical use. METHODS: Through a combination of screening and rational design, we identified a cardiac reprogramming cocktail that can be encoded in a single adeno-associated virus. We also created a novel adeno-associated virus capsid that can transduce cardiac fibroblasts more efficiently than available parental serotypes by mutating posttranslationally modified capsid residues. Because a constitutive promoter was needed to drive high expression of these cell fate–altering reprogramming factors, we included binding sites to a cardiomyocyte-restricted microRNA within the 3’ untranslated region of the expression cassette that limits expression to nonmyocytes. After optimizing this expression cassette to reprogram human cardiac fibroblasts into induced cardiomyocyte-like cells in vitro, we also tested the ability of this capsid/cassette combination to confer functional benefit in acute mouse myocardial infarction and chronic rat myocardial infarction models. RESULTS: We demonstrated sustained, dose-dependent improvement in cardiac function when treating a rat model 2 weeks after myocardial infarction, showing that cardiac reprogramming, when delivered in a single, clinically relevant adeno-associated virus vector, can support functional improvement in the postremodeled heart. This benefit was not observed with GFP (green fluorescent protein) or a hepatocyte reprogramming cocktail and was achieved even in the presence of immunosuppression, supporting myocyte formation as the underlying mechanism. CONCLUSIONS: Collectively, these results advance the application of cardiac reprogramming gene therapy as a viable therapeutic approach to treat chronic heart failure resulting from ischemic injury.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myocardial InfarctionMicroRNAsRatsMiceHumansAnimalsDependovirusMyocytes, CardiacGenetic TherapyGreen Fluorescent ProteinsCellular ReprogrammingFibroblasts

Stichwörter der Autor:innen

adeno-associated virusdirect cell reprogramming techniquesgene therapyischemic heart diseaseregeneration

Substanzen

MicroRNAsGreen Fluorescent Proteins

Autor:innen und Institutionen

  • Tenaya Therapeutics, Inc, South San Francisco, CA (H.Z., J.Y., C.S., A.Z., I.W., E.C.L., T.N.Q., C.A.R., E.R.N., E.X., Z.D., T.M.A.M., F.F., A.F., J. Liu, S.J., C.F., T.W.C., F.J., W.S.P., J. Lin, T.H., K.N.I., L.M.L.).
  • Gladstone Institutes, San Francisco, CA (P.Y., D.S.).
  • Roddenberry Center for Stem Cell Biology and Medicine at Gladstone, San Francisco, CA (D.S.).
  • Division of Cardiology, Department of Pediatrics, School of Medicine (D.S.), University of California San Francisco.
  • Department of Biochemistry and Biophysics (D.S.), University of California San Francisco.

ORCID-Profile: Chetan Srinath, Emily R Nettesheim, Zoe Duclos, Tamer M A Mohamed, Farshad Farshidfar, Deepak Srivastava, Kathryn N Ivey, Laura M Lombardi

Zitieren

APA

Zhou, H., Yang, J., Srinath, C., Zeng, A., Wu, I., Leon, E. C., Qureshi, T. N., Reid, C. A., Nettesheim, E. R., Xu, E., Duclos, Z., Mohamed, T. M. A., Farshidfar, F., Fejes, A., Liu, J., Jones, S., Feathers, C., Chung, T. W., Jing, F., …, & Lombardi, L. M. (2023). Improved Cardiac Function in Postischemic Rats Using an Optimized Cardiac Reprogramming Cocktail Delivered in a Single Novel Adeno-Associated Virus. Circulation, 148(14), 1099-1112. https://doi.org/10.1161/circulationaha.122.061542

Vancouver

Zhou H, Yang J, Srinath C, Zeng A, Wu I, Leon EC, et al. Improved Cardiac Function in Postischemic Rats Using an Optimized Cardiac Reprogramming Cocktail Delivered in a Single Novel Adeno-Associated Virus. Circulation. 2023;148(14):1099-1112. doi:10.1161/circulationaha.122.061542

BibTeX
@article{Zhou2023,
  author = {Zhou, Huanyu and Yang, Jin and Srinath, Chetan and Zeng, Aliya and Wu, Iris and Leon, Elena C and Qureshi, Tawny Neal and Reid, Christopher A and Nettesheim, Emily R and Xu, Emma and Duclos, Zoe and Mohamed, Tamer M A and Farshidfar, Farshad and Fejes, Anthony and Liu, Jun and Jones, Samantha and Feathers, Charles and Chung, Tae Won and Jing, Frank and Prince, William S and Lin, JianMin and Yu, Pengzhi and Srivastava, Deepak and Hoey, Timothy and Ivey, Kathryn N and Lombardi, Laura M},
  title = {Improved Cardiac Function in Postischemic Rats Using an Optimized Cardiac Reprogramming Cocktail Delivered in a Single Novel Adeno-Associated Virus},
  journal = {Circulation},
  year = {2023},
  volume = {148},
  number = {14},
  pages = {1099--1112},
  doi = {10.1161/circulationaha.122.061542}
}
Kostenlos starten →